Kymera Therapeutics, Inc.
$200 Million Initial Public Offering
ICR Westwicke began working with biopharmaceutical company Kymera Therapeutics in April 2020, providing strategic advice for the company’s IPO, throughout the underwriter selection process, S-1 drafting process, and four-day virtual roadshow. In August 2020, Kymera priced its upsized IPO at $20 per share.
Download the case study to learn how ICR Westwicke’s strategic advice led to a successful IPO, with shares closing up 66.3%.